Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Arcturus Therapeutics Holdings Inc. (ARCT)

16.16   0.42 (2.67%) 07-02 16:01
Open: 15.7 Pre. Close: 15.74
High: 16.56 Low: 15.2265
Volume: 683,451 Market Cap: 427(M)
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 16.58 - 16.64 16.64 - 16.71
Low: 15.07 - 15.14 15.14 - 15.21
Close: 16.04 - 16.15 16.15 - 16.27

Technical analysis

as of: 2022-07-01 4:20:06 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 20.48     One year: 24.7
Support: Support1: 11.69    Support2: 9.73
Resistance: Resistance1: 17.54    Resistance2: 21.14
Pivot: 14.61
Moving Average: MA(5): 15.7     MA(20): 15.45
MA(100): 20.79     MA(250): 32.63
MACD: MACD(12,26): -0.7     Signal(9): -1
Stochastic oscillator: %K(14,3): 73.3     %D(3): 58.7
RSI: RSI(14): 49.6
52-week: High: 65  Low: 11.69
Average Vol(K): 3-Month: 810 (K)  10-Days: 1,010 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ARCT ] has closed below upper band by 21.1%. Bollinger Bands are 39.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sat, 02 Jul 2022
ArbitrageCT (ARCT): How Does the Chart Look Saturday? - InvestorsObserver

Tue, 28 Jun 2022
EACO committed to firm management of communication services in EAC - The Citizen

Tue, 28 Jun 2022
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Sat, 11 Jun 2022
ArbitrageCT (ARCT) Rises 24.48% Saturday: What's Next for This Very Bullish Rated Crypto? - InvestorsObserver

Mon, 06 Jun 2022
Arcturus: Potential Based On Rare Disease Therapy ARCT-810 (NASDAQ:ARCT) - Seeking Alpha

Wed, 11 May 2022
These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 26 (M)
% Held by Insiders 2.271e+007 (%)
% Held by Institutions 13.8 (%)
Shares Short 2,590 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.0166e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 641.3
Return on Equity (ttm) -29.2
Qtrly Rev. Growth 1.236e+007
Gross Profit (p.s.) 57.99
Sales Per Share -23.8
EBITDA (p.s.) 4.51095e+006
Qtrly Earnings Growth -7.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -135 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.68
Price to Cash Flow 4.5

Stock Dividends

Dividend 0
Forward Dividend 3.05e+006
Dividend Yield 0%
Dividend Pay Date 2017-11-15
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.